And the sad truth is if he took an objective approach and was a little more academic in his research he could have 1) announced he was taking a bullish position in the stock like the rest of us; and 2) reported on it's legitimate standing in the AD biotech space and ultimately profited like the rest of us on the sound science that supports AVXL.